632 related articles for article (PubMed ID: 9512972)
1. Disease-specific noncompliance with drug treatment as a cause of persistent hyperuricemia and gout in anorexia nervosa.
Gröbner W; Walter-Sack I; de Vries JX
Eur J Med Res; 1998 Feb; 3(1-2):77-80. PubMed ID: 9512972
[TBL] [Abstract][Full Text] [Related]
2. [Long lasting normalization of uric acid after combination therapy with 300 mg allopurinol and 60 mg benzbromarone in patients with gout and hyperuricemia].
Matzkies F
Med Klin (Munich); 1992 Sep; 87(9):460-2. PubMed ID: 1406482
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol.
Reinders MK; van Roon EN; Jansen TL; Delsing J; Griep EN; Hoekstra M; van de Laar MA; Brouwers JR
Ann Rheum Dis; 2009 Jan; 68(1):51-6. PubMed ID: 18250112
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of benzbromarone compared to allopurinol in lowering serum uric acid level in hyperuricemic patients.
Hanvivadhanakul P; Akkasilpa S; Deesomchok U
J Med Assoc Thai; 2002 Jun; 85 Suppl 1():S40-7. PubMed ID: 12188443
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of combined low dose of Allopurinol and benzbromarone compared to standard dose of Allopurinol in hyperuricemia.
Akkasilpa S; Osiri M; Deesomchok U; Avihingsanon Y
J Med Assoc Thai; 2004 Sep; 87(9):1087-91. PubMed ID: 15516011
[TBL] [Abstract][Full Text] [Related]
6. [Clinical studies on hyperuricemia and gout after transplantation].
Imanishi M; Ikegami M; Ishii T; Nishioka T; Uemura T; Kunikata S; Kanda H; Matsuura T; Akiyama T; Kurita T
Hinyokika Kiyo; 1990 Aug; 36(8):893-6. PubMed ID: 2239590
[TBL] [Abstract][Full Text] [Related]
7. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
[TBL] [Abstract][Full Text] [Related]
8. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level.
Siu YP; Leung KT; Tong MK; Kwan TH
Am J Kidney Dis; 2006 Jan; 47(1):51-9. PubMed ID: 16377385
[TBL] [Abstract][Full Text] [Related]
9. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis.
Halpern R; Mody RR; Fuldeore MJ; Patel PA; Mikuls TR
Curr Med Res Opin; 2009 Jul; 25(7):1711-9. PubMed ID: 19485724
[TBL] [Abstract][Full Text] [Related]
10. Hereditary nephropathy associated with hyperuricemia and gout.
Puig JG; Miranda ME; Mateos FA; Picazo ML; Jiménez ML; Calvin TS; Gil AA
Arch Intern Med; 1993 Feb; 153(3):357-65. PubMed ID: 8427538
[TBL] [Abstract][Full Text] [Related]
11. Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease.
Panomvana D; Sripradit S; Angthararak S
J Clin Rheumatol; 2008 Feb; 14(1):6-11. PubMed ID: 18431090
[TBL] [Abstract][Full Text] [Related]
12. [Effectiveness and tolerance of long-term uricosuric treatment].
Berg H
Z Gesamte Inn Med; 1990 Dec; 45(23):719-20. PubMed ID: 2102029
[TBL] [Abstract][Full Text] [Related]
13. [Effect of uric acid lowering drugs in low dosage in patients with hyperuricemia and hypertriglyceridemia in a randomized group study].
Arntz HR; Dreykluft HR; Leonhardt H
Fortschr Med; 1979 Jul; 97(27):1212-4. PubMed ID: 457017
[TBL] [Abstract][Full Text] [Related]
14. [A study of serum oxipurinol concentration and renal function in patients administered allopurinol].
Saji M
Nihon Jinzo Gakkai Shi; 1996 Dec; 38(12):640-50. PubMed ID: 9014485
[TBL] [Abstract][Full Text] [Related]
15. [The use of allopurinol in long-term treatments for optimal effect].
Fenner H
Fortschr Med; 1980 Mar; 98(10):(373-6). PubMed ID: 7372221
[TBL] [Abstract][Full Text] [Related]
16. Uric acid lowering effect of oxipurinol sodium in hyperuricemic patients - therapeutic equivalence to allopurinol.
Walter-Sack I; de Vries JX; Ernst B; Frei M; Kolb S; Kosmowski J; Priebe U; Schroder HE; Slotty C; Voss A; Weber A; Wegscheider K
J Rheumatol; 1996 Mar; 23(3):498-501. PubMed ID: 8832991
[TBL] [Abstract][Full Text] [Related]
17. [The effect of benzbromaron in gout patients with limited kidney function].
Kuzmits R; Bresnik W; Müller MM
Fortschr Med; 1979 Nov; 97(44):2057-61. PubMed ID: 511087
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C
J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of hyperuricaemia with a combination of allopurinol and benzbromaron (author's transl)].
Matzkies F; Berg G
Dtsch Med Wochenschr; 1976 Oct; 101(43):1568-70. PubMed ID: 991731
[TBL] [Abstract][Full Text] [Related]
20. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout.
Perez-Ruiz F; Calabozo M; Pijoan JI; Herrero-Beites AM; Ruibal A
Arthritis Rheum; 2002 Aug; 47(4):356-60. PubMed ID: 12209479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]